Aspirin Rarely Used for Colorectal Cancer Prevention Despite New Evidence

New research from the CaPP3 study suggests that a low daily dose of 100 milligrams of aspirin may effectively reduce colorectal cancer risk in people with Lynch syndrome, a hereditary condition that significantly increases cancer susceptibility. Building on previous findings from the CAPP2 study using a higher 600-milligram dose, this lower dose appears to provide similar cancer-preventive benefits while minimizing side effects like bleeding complications. Lynch syndrome carriers face substantially elevated risks of colorectal and other cancers, making preventive strategies crucial. The findings, published in The Lancet Gastroenterology & Hepatology, suggest aspirin could offer a safer, more tolerable option for high-risk patients, though adoption remains limited in clinical practice.